PT3220916T - Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida - Google Patents

Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida

Info

Publication number
PT3220916T
PT3220916T PT158606764T PT15860676T PT3220916T PT 3220916 T PT3220916 T PT 3220916T PT 158606764 T PT158606764 T PT 158606764T PT 15860676 T PT15860676 T PT 15860676T PT 3220916 T PT3220916 T PT 3220916T
Authority
PT
Portugal
Prior art keywords
methyl
morpolinomethyl
piran
dihydropyridin
carboxamide
Prior art date
Application number
PT158606764T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Eisai R&D Man Co Ltd
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Epizyme Inc filed Critical Eisai R&D Man Co Ltd
Publication of PT3220916T publication Critical patent/PT3220916T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PT158606764T 2014-11-17 2015-11-17 Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida PT3220916T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06

Publications (1)

Publication Number Publication Date
PT3220916T true PT3220916T (pt) 2023-06-26

Family

ID=56014476

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158606764T PT3220916T (pt) 2014-11-17 2015-11-17 Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida

Country Status (20)

Country Link
US (3) US10786511B2 (OSRAM)
EP (2) EP3220916B1 (OSRAM)
JP (3) JP6829684B2 (OSRAM)
KR (3) KR20240035908A (OSRAM)
CN (2) CN107249591B (OSRAM)
AU (3) AU2015350108B2 (OSRAM)
BR (1) BR112017010166A2 (OSRAM)
DK (1) DK3220916T3 (OSRAM)
EA (1) EA201791095A1 (OSRAM)
ES (1) ES2947819T3 (OSRAM)
FI (1) FI3220916T3 (OSRAM)
HU (1) HUE062159T2 (OSRAM)
IL (4) IL296080B2 (OSRAM)
LT (1) LT3220916T (OSRAM)
MX (2) MX383484B (OSRAM)
PL (1) PL3220916T3 (OSRAM)
PT (1) PT3220916T (OSRAM)
SG (1) SG11201703806XA (OSRAM)
SI (1) SI3220916T1 (OSRAM)
WO (1) WO2016081523A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9688665B2 (en) 2012-10-15 2017-06-27 Epizyme, Inc. Methods of treating cancer
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
LT3157527T (lt) 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitoriai, skirti limfomos gydymui
US10786511B2 (en) 2014-11-17 2020-09-29 Epizyme, Inc. Method for treating cancer
WO2016172199A1 (en) 2015-04-20 2016-10-27 Epizyme, Inc. Combination therapy for treating cancer
WO2016201328A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
SG10201909199PA (en) 2015-08-24 2019-11-28 Epizyme Inc Method for treating cancer
CA3011186A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
EP3572095A4 (en) 2017-01-19 2020-11-18 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of htlv-1-associated myelopathy
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
EP3678663A4 (en) 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
BR112022012258A2 (pt) * 2019-12-20 2022-08-30 Epizyme Inc Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
US20250276079A1 (en) 2022-04-27 2025-09-04 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH EZH1 and/or EZH2 INHIBITOR

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
WO2008121476A1 (en) * 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
AU2011298987B2 (en) * 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130296325A1 (en) * 2011-01-14 2013-11-07 Bristol-Myers Squibb Company HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
ES2718900T3 (es) * 2012-03-12 2019-07-05 Epizyme Inc Inhibidores de EZH2 humana y métodos de uso de los mismos
MX367793B (es) * 2012-04-13 2019-09-06 Epizyme Inc Terapia de combinación para tratar cáncer.
BR112014025508B1 (pt) * 2012-04-13 2020-11-17 Eisai R&D Management Co., Ltd. forma de sal de um inibidor de histona metiltransferase ezh2 humana
US9688665B2 (en) * 2012-10-15 2017-06-27 Epizyme, Inc. Methods of treating cancer
JP6461803B2 (ja) 2012-10-15 2019-01-30 エピザイム，インコーポレイティド 置換ベンゼン化合物
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
EP2935214B1 (en) 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZOL COMPOUNDS
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
EA038869B1 (ru) * 2013-10-16 2021-10-29 Эпизим, Инк. Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
JP2016533364A (ja) * 2013-10-18 2016-10-27 エピザイム，インコーポレイティド 癌を処置する方法
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
LT3157527T (lt) * 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitoriai, skirti limfomos gydymui
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
IL289947B2 (en) 2014-10-16 2024-06-01 Epizyme Inc Method for treating cancer
US10786511B2 (en) * 2014-11-17 2020-09-29 Epizyme, Inc. Method for treating cancer
WO2016201328A1 (en) * 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
MA45406A (fr) * 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer

Also Published As

Publication number Publication date
CN107249591A (zh) 2017-10-13
US12168014B2 (en) 2024-12-17
IL304252A (en) 2023-09-01
IL296080A (en) 2022-11-01
KR20170103768A (ko) 2017-09-13
AU2024201171B2 (en) 2026-01-29
JP2017537899A (ja) 2017-12-21
KR102644844B1 (ko) 2024-03-07
EP3220916A1 (en) 2017-09-27
NZ768247A (en) 2024-05-31
JP7485810B2 (ja) 2024-05-16
IL296080B1 (en) 2023-08-01
JP2021073241A (ja) 2021-05-13
AU2015350108A1 (en) 2017-05-25
MX383484B (es) 2025-03-11
PL3220916T3 (pl) 2023-08-14
IL252182B (en) 2022-10-01
ES2947819T3 (es) 2023-08-21
EP3220916B1 (en) 2023-04-19
US20170360797A1 (en) 2017-12-21
NZ731696A (en) 2024-03-22
MX2017006089A (es) 2017-12-11
KR20210156840A (ko) 2021-12-27
US10786511B2 (en) 2020-09-29
AU2015350108B2 (en) 2021-04-08
KR20240035908A (ko) 2024-03-18
CA2967664A1 (en) 2016-05-26
CN107249591B (zh) 2024-01-30
CN116650500A (zh) 2023-08-29
AU2024201171A1 (en) 2024-03-14
IL252182A0 (en) 2017-07-31
IL252182B2 (en) 2023-02-01
SI3220916T1 (sl) 2023-09-29
HUE062159T2 (hu) 2023-10-28
AU2021204706A1 (en) 2021-07-29
IL323396A (en) 2025-11-01
SG11201703806XA (en) 2017-06-29
EP4272742A1 (en) 2023-11-08
JP2023062189A (ja) 2023-05-02
JP6829684B2 (ja) 2021-02-10
US20250064822A1 (en) 2025-02-27
BR112017010166A2 (en) 2018-02-14
DK3220916T3 (da) 2023-06-26
KR102338802B1 (ko) 2021-12-14
LT3220916T (lt) 2023-07-25
IL296080B2 (en) 2023-12-01
WO2016081523A1 (en) 2016-05-26
FI3220916T3 (fi) 2023-06-19
EA201791095A1 (ru) 2017-10-31
AU2021204706B2 (en) 2023-11-23
EP3220916A4 (en) 2018-07-11
MX2021006734A (es) 2021-07-02
US20210060030A1 (en) 2021-03-04
IL304252B1 (en) 2025-11-01

Similar Documents

Publication Publication Date Title
PT3220916T (pt) Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida
IL285114A (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
IL256056A (en) Ezh2 inhibitors for treating lymphoma
IL258402B1 (en) Electroporation for obesity or diabetes treatment
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
LT3468965T (lt) 1-tetrahidropiranilkarbonil-2,3-dihidro-1h-indolo junginiai vėžio gydymui
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
LT3184523T (lt) N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
HUE057426T2 (hu) Heteroaril-szubsztituált béta-hidroxietilamin-származékok magas vécukorszint kezelésére való alkalmazásra
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
PT3377516T (pt) Composição para o tratamento do cancro
EA201790785A1 (ru) Производные тетрагидроизохинолина
MX2016004703A (es) Forma salina de hidrocloruro para la inhibicion de ezh2.
IL254779A0 (en) Methods of administering glutaminase inhibitors
HUE049413T2 (hu) Nazális porkészítmény hipoglikémia kezelésére
PT3572410T (pt) Análogos dioxolano de uridina para o tratamento de cancro
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
IL256103B (en) Compositions and methods for treating celiac sprue disease
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
HUE045226T2 (hu) Herbicid hatású N-(1,3,4-oxadiazol-2-il)arilkarboxamid-származékok
IL282041A (en) Egfr inhibitors for treating keratodermas
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi